RT Journal Article
SR Electronic
T1 Augmented curation of clinical notes of COVID-19 and influenza patients reveals that long-term neuropsychiatric and coagulopathic symptoms are more associated with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.03.20248997
DO 10.1101/2021.01.03.20248997
A1 Martin, Jacob T.
A1 Akama-Garren, Elliot
A1 Puranik, Arjun
A1 Liukasemsarn, Saran
A1 Venkatakrishnan, AJ
A1 O’Horo, John C.
A1 Hurt, Ryan T.
A1 Williams, Amy W.
A1 Gores, Gregory J.
A1 Halamka, John
A1 Badley, Andrew D.
A1 Awasthi, Samir
A1 Soundararajan, Venky
YR 2021
UL http://medrxiv.org/content/early/2021/01/05/2021.01.03.20248997.abstract
AB Less than one year into the COVID-19 pandemic, over 70 million individuals worldwide have been infected and case counts continue to accelerate, yet the long-term sequelae of COVID-19 are unknown. We leverage ‘augmented curation’ to extract symptoms and signs occurring post – COVID as noted in follow up physician’s notes of COVID-19 patients at the Mayo Clinic who were diagnosed with SARS-CoV-2 infection between March and September 2020, or influenza between 2014 and 2019. We compare the chart prevalence of signs/symptoms and diseases in the 3-to-6 month post-diagnosis vs. 1-to-6 month pre-diagnosis period for each disease, and subsequently compare the observed effect size of each symptom across the two diseases. Relative to post-influenza, we observe a significant increase in the chart prevalence of terms including “depression”, “anxiety”, “obesity”, and “bleeding” in COVID-19 patients under the age of 55. Across all age groups, “nodules” and “cysts” were also significantly increased. These findings compel targeted investigations into what may be persistent neuropsychiatric, pulmonary, metabolic, and coagulopathic phenotypes following SARS-CoV2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding supported this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Mayo Clinic Institutional Review Board as a minimal risk study (IRB 20-003278, 'Study of COVID-19 patient characteristics with augmented curation of Electronic Health Records (EHR) to inform strategic and operational decisions'). Subjects were excluded if they did not have a research authorization on file.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAfter publication, the data will be made available to others upon reasonable requests to the corresponding author. A proposal with detailed description of study objectives and statistical analysis plan will be needed for evaluation of the reasonability of requests. Deidentified data will be provided after approval from the corresponding author and the Mayo Clinic standard IRB process for such requests.